Hepatitis C reinfection after sustained virological response.
about
Impact of Hepatitis C Treatment as Prevention for People Who Inject Drugs is sensitive to contact network structure.Structural flexibility at a major conserved antibody target on hepatitis C virus E2 antigen.Native Folding of a Recombinant gpE1/gpE2 Heterodimer Vaccine Antigen from a Precursor Protein Fused with Fc IgG.Review article: treatment as prevention - targeting people who inject drugs as a pathway towards hepatitis C eradication.Direct-acting antiviral agents for HCV infection affecting people who inject drugs.Hepatitis C: Review of the Epidemiology, Clinical Care, and Continued Challenges in the Direct Acting Antiviral Era.Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs.HCV Cure and Reinfection Among People With HIV/HCV Coinfection and People Who Inject Drugs.Hepatitis C virus vaccine candidates inducing protective neutralizing antibodies.The cost impact of outreach testing and treatment for hepatitis C in an urban Drug Treatment Unit.Elimination of HCV as a public health concern among people who inject drugs by 2030 - What will it take to get there?Prevalence of hepatitis C and pre-testing awareness of hepatitis C status in 1500 consecutive PWID participants at the Stockholm needle exchange program.Treatment and primary prevention in people who inject drugs for chronic hepatitis C infection: is elimination possible in a high-prevalence setting?HCV reinfection incidence among individuals treated for recent infection.Late Relapse Versus Hepatitis C Virus Reinfection in Patients With Sustained Virologic Response After Sofosbuvir-Based Therapies.The HCV care continuum does not end with cure: A call to arms for the prevention of reinfection.Hepatitis C cross-genotype immunity and implications for vaccine developmentThe Rationale for a Preventative HCV Virus-Like Particle (VLP) Vaccine.Hepatitis C virus prevention and treatment prioritization-ethical, economic and evidential dimensions of early rather than delayed treatment for people who inject drugs.Understanding and addressing hepatitis C reinfection in the oral direct acting antiviral era.Sofosbuvir-Based Direct-Acting Antiviral Therapies for HCV in People Receiving Opioid Substitution Therapy: An Analysis of Phase 3 Studies.Rapid changes in peripheral lymphocyte concentrations during interferon-free treatment of chronic hepatitis C virus infection.Outpatient directly observed therapy for hepatitis C among people who use drugs: a systematic review and meta-analysis.Direct-acting antiviral treatment in real world patients with hepatitis C not associated with psychiatric side effects: a prospective observational study.Mapping Determinants of Virus Neutralization and Viral Escape for Rational Design of a Hepatitis C Virus Vaccine.Immunological responses following administration of a genotype 1a/1b/2/3a quadrivalent HCV VLP vaccine.Risk factors for familial clustering of hepatitis C virus infection in a Chinese Han population: a cross-sectional study.Management of Patients Who Have Achieved Sustained Virologic Response for Hepatitis C Virus Infection.Beyond cure: patient reported outcomes of hepatitis C treatment among people who inject drugs in Australia
P2860
Q33687240-5E216ECF-67CB-43AF-9E2C-0D21D36B920EQ37417839-7B584ECD-24A4-487C-95C0-CAF28456296FQ37512845-513C8116-CE26-4A8C-AA21-0B92B26CC2E2Q38380343-A2EDD38F-8D39-4AE5-A7BF-447A5803DE12Q38613271-4A863210-4455-4AE8-8BDB-37658794FD42Q38635796-D9069556-C91F-4B6F-8334-DCA2191A076BQ38661825-D45C443D-486A-4E4B-99B2-1D238D949E19Q38692113-8CD58C48-6A0E-4FF3-95FE-B040736A49FBQ38856649-A3D802E7-7A2B-42BA-94AB-6043C5A87E6FQ39449112-CDC7AC22-1148-4C19-B6D5-378F34FCFD2BQ40092669-DACE449A-0220-41DB-AAB1-73407B2E4CDBQ40176014-918E7CA0-A9C0-40A3-A449-5374815178E3Q40364008-FF259729-9F25-4264-81AE-2BA98D6C6156Q40393982-FB1A5683-2833-4C25-865B-4FD86F0551F9Q40466129-E183FD7C-EE19-43DB-B9B3-4A44E6B3E0D3Q42338341-B6BD53F2-E7CD-4423-9B23-DBA4D24D509EQ42364607-E633C319-187E-4F9C-8477-1DDBBD0FE3CEQ45324462-FCDD5211-C4B7-43FB-AE87-CE7595DFE94FQ45333992-85EE1B28-7579-40F9-A7C5-C948DA003A3CQ47274505-6861DF82-2892-468B-9A27-261F7AAB35D5Q49953662-01A892DD-C7D4-4FA4-BF7C-BF7B8F53582BQ52741770-1FEB0D22-AD40-4FFB-894E-E5D49B5172F7Q53281101-5C05D0D0-BAC8-45A5-BFE7-A85F7C9B2D43Q55050518-91E117AA-439D-4462-9010-C7C76A8EE467Q55282191-C1B96A53-1297-4E69-A3B1-74A7FEB0D2BDQ55303632-3A448370-5DE9-4782-94EE-80D604ED0740Q55396689-2E636EB0-EF02-4E98-B35D-2B567043264DQ55477214-303922F4-9E96-44D9-A63D-B4573556D1AAQ57169238-EC5FCF75-CC8A-4338-ACE2-C947F0A3346D
P2860
Hepatitis C reinfection after sustained virological response.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Hepatitis C reinfection after sustained virological response.
@en
type
label
Hepatitis C reinfection after sustained virological response.
@en
prefLabel
Hepatitis C reinfection after sustained virological response.
@en
P2093
P1476
Hepatitis C reinfection after sustained virological response.
@en
P2093
Arild Mæland
Benedikte Bjøro
Dagny H Dorenberg
Hege Kileng
Håvard Midgard
Jetmund O Ringstad
Jørn Paulsen
Kathrine Stene-Johansen
Lars Heggelund
Lars N Karlsen
P304
P356
10.1016/J.JHEP.2016.01.001
P577
2016-01-09T00:00:00Z